Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847288 · ClinicalTrials.gov registry record · Phase 4
OptiVol® Care Pathway
A Phase 4 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,682
- Enrollment target
NCT00847288: Completed Phase 4 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00847288 is a Phase 4 study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 1,682 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00847288, a Phase 4 study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,682 participants
- Enrollment target
Study Summary
Medtronic, Inc. is sponsoring the OptiVol® Care Pathway Study, a prospective, randomized, multi-center, post-market clinical trial in the United States. The purpose of this clinical trial is to compare monthly versus quarterly review of Cardiac Compass® Trends with OptiVol for initiation of clinical action. It is hypothesized that monthly review of Cardiac Compass Trends with OptiVol will shorten time to clinical action as compared to quarterly review.
Interventions
- OTHER Monthly Review Arm
- OTHER Quarterly Review Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,682 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
What the finished NCT00847288 record still lists
NCT00847288 is an interventional study that assigns participants to a tested intervention. Its 1,682 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 2 interventions - of which Monthly Review Arm is the first listed.
NCT00847288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00847288 about?
NCT00847288 is a clinical study titled "OptiVol® Care Pathway". Medtronic, Inc. is sponsoring the OptiVol® Care Pathway Study, a prospective, randomized, multi-center, post-market clinical trial in the United States. The purpose of this clinical trial is to compare monthly versus quarterly review of Cardiac Compass® Trends with OptiVol for initiation of clinical...
What is the current status of trial NCT00847288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,682 participants. The study started on 2009-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00847288?
The interventions under investigation include: Monthly Review Arm (OTHER), Quarterly Review Arm (OTHER).
Who is sponsoring clinical trial NCT00847288?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00847288's enrollment target sits among peer trials
1,682 47th of 2000 higher than 1,954 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia